Eli Lilly (LLY) and its competitors have gained new insights from a major study published in the journal Nature, which links GLP1R/GIPR genetic variations to modest differences in weight loss and side effect risks associated with semaglutide and tirzepatide. The findings support the development of future precision medicine strategies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.